Comparative evaluation of radionuclide therapy using ^90Y and ^177Lu

[1]  M. Pavel,et al.  Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Xiufen Zou,et al.  Mathematical modeling and dynamical analysis of anti-tumor drug dose-response. , 2022, Mathematical biosciences and engineering : MBE.

[3]  K. Nackaerts,et al.  Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies , 2021, Cancers.

[4]  D. Srikrishna,et al.  We need to bring R0 < 1 to treat cancer too , 2021, Genome medicine.

[5]  D. Srikrishna,et al.  We need to bring R0 < 1 to treat cancer too , 2021, Genome Medicine.

[6]  E. Scarpi,et al.  Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials , 2021, ESMO open.

[7]  M. Mazinani,et al.  Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code , 2021, Journal of biomedical physics & engineering.

[8]  T. Higashi,et al.  Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP , 2020, Annals of Nuclear Medicine.

[9]  U. Haberkorn,et al.  Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617 , 2018, The Journal of Nuclear Medicine.

[10]  Y. Tsushima,et al.  Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase. , 2018, Molecular pharmaceutics.

[11]  P. Lambin,et al.  Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms , 2018, Oncotarget.

[12]  Y. Tsushima,et al.  Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET , 2018, Breast Cancer.

[13]  Tatsuhiko Sato,et al.  Evaluation of the accuracy of mono-energetic electron and beta-emitting isotope dose-point kernels using particle and heavy ion transport code system: PHITS. , 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[15]  Y. Tsushima,et al.  Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts , 2017, Annals of Nuclear Medicine.

[16]  S. Severi,et al.  Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life , 2017, OncoTargets and therapy.

[17]  S. Larson,et al.  Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.

[18]  Y. Tsushima,et al.  Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody. , 2014, Cancer biotherapy & radiopharmaceuticals.

[19]  L. Królicki,et al.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  C. R. Leemans,et al.  (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  W. Oyen,et al.  Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  G. Griffiths,et al.  Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  H. Hanaoka,et al.  Production of highly purified no-carrier-added 177Lu for radioimmunotherapy , 2014, Journal of Radioanalytical and Nuclear Chemistry.

[25]  P. Little,et al.  The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma , 2014, Targeted Oncology.